The digital health sector is benefitting big-time from the explosion in drug discovery transactions in 2017. Investors are now targeting eHealth companies specializing in clinical trial software.
After 34 announced transactions in 2017, the news that one contract research organization (CRO) bought another CRO is downright yawn-inducing. This space is undergoing rapid consolidation, no question. Before this week, those 34 deals had a combined total of approximately $20.9 billion. Add another deal, and another $950 million, and the market just got a […]
A few CROs, like PRA Health Sciences, are turning to eHealth acquisitions to strengthen their data technology capabilities.
In late July, Laboratory Corp. of America Holdings (NYSE: LH) announced the 6th CRO deal to surpass the $1 billion mark this year. The $1.2 billion deal for Chiltern is its third announced transaction this year, having acquired Mount Sinai’s Clinical Outreach Laboratories (January) and Pathology Associates Medical Laboratories, LLC (February).
Halfway through 2017, a large number of publicly traded healthcare companies are going private, thanks to the large amount of money held by financial buyers.
Pamplona Capital Management was on the hunt for a contract research organization (CRO). After missing out on PPD, the PE firm bagged publicly traded PAREXEL for $5.2 billion.
Health care investors are moving out of sectors that could be hit with federal funding cuts, or become vilified in the media.
Contract research organizations (CROs) are hot targets this year. The heavy demand by pharma and biotech companies is attracting large private equity buyers.
Patheon N.V., formerly Patheon, Inc., has been acquired by Thermo Fisher Scientific for $7.2 billion. This deal marks the largest year-to-date in the contract development and manufacturing market.
The CRO market is a favorite of private equity investors, and M&A activity has been strong in the first half of 2017.